The study was designed to extend retrospectively the analysis of a previously reported study on chronic bronchitis patients with acute exacerbations treated with amoxicillin-clavulanic acid or matched placebo. We retrospectively re-clustered patients on the basis of severity of baseline lung function: Cluster 1 (104 patients) mean screening FEV 1 32.67±6.83 (SD); Cluster 2 (109 patients) mean screening FEV 1 54.12±5.56; Cluster 3 (122 patients) mean screening FEV 1 71.54±5.51. The success rate in the antibiotic group was significantly greater compared to the placebo group (P2 test). The differences in final FEV 1 values in the treatment group and placebo group were significantly different (P 1 values showed an improvement following antibiotic treatment and worsening after placebo (P1 values was not significant for both treatment groups. Our patients with severe functional impairment and higher number of exacerbations per year are those who derive the greatest benefit from antibiotic treatment.
- Lung function
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine